产品介绍 |
U-69593 是一种有效且选择性的 κ1阿片受体 激动剂。U-69593 减弱成瘾剂诱导的大鼠行为敏化作用。U-69593 可减轻小鼠的焦虑并增强自发交替记忆。U-69593 降低腹侧纹状体中多巴胺和谷氨酸的钙依赖性透析液水平 [4]。
|
---|
生物活性 |
U-69593 is a potent and selective κ1-opioid receptor agonist. U-69593 attenuates addictive agent-induced behavioral sensitization in the rat. U-69593 reduces anxiety and enhances spontaneous alternation memory in mice. U-69593 reduces calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum[4].
|
---|
体外研究 | |
---|
体内研究 |
U-69593 (0.16 mg/kg;sc) 减轻成瘾剂诱导的大鼠行为敏化。 U-69593 (1、10、25 nmol/μL;显微注射) 减少小鼠的焦虑并增强自发交替记忆。 U-69593 (0.32 mg/kg;sc) 降低急性苯丙胺诱发的行为和钙依赖性透析液中多巴胺和腹侧纹状体中的谷氨酸[4]。
西域 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: |
Rat |
Dosage: |
0.16 mg/kg |
Administration: |
S.c. (an acute injection of cocaine (20 mg/kg i.p.)) |
Result: |
Attenuated the acute and chronic effects of cocaine on locomotor activity and stereotypy. |
Animal Model: |
CD-1 mice |
Dosage: |
1, 10, 25 nmol/µL |
Administration: |
Microinjection (in the infralimbic cortex (IL)), once every week, 2 weeks |
Result: |
Dose-dependently prolonged transfer-latency (T-L) and produced a dose-dependent anxiolytic behavioural profile, and after 24 h, the mouse were observed small but detectable carry-over effects. In week 2, U-69593 dose-dependently prolonged T/L and produced an anxiolytic behavioural profile in the first EPM (elevated plus-maze) trial, but observed a robust anxiolytic behavioural profile. |
Animal Model: |
280-350 g, male Wistar rats[4] |
Dosage: |
0.32 mg/kg |
Administration: |
S.c. (followed 15 min later by an injection of amphetamine (2.5 mg/kg i.p.)) |
Result: |
Significantly reduced the amphetamine-stimulated increase in dialysate dopamine levels and blocked the ability of amphetamine to evoke an increase in dialysate glutamate levels. |
|
---|
体内研究 |
U-69593 (0.16 mg/kg;sc) 减轻成瘾剂诱导的大鼠行为敏化。 U-69593 (1、10、25 nmol/μL;显微注射) 减少小鼠的焦虑并增强自发交替记忆。 U-69593 (0.32 mg/kg;sc) 降低急性苯丙胺诱发的行为和钙依赖性透析液中多巴胺和腹侧纹状体中的谷氨酸[4]。
西域 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: |
Rat |
Dosage: |
0.16 mg/kg |
Administration: |
S.c. (an acute injection of cocaine (20 mg/kg i.p.)) |
Result: |
Attenuated the acute and chronic effects of cocaine on locomotor activity and stereotypy. |
Animal Model: |
CD-1 mice |
Dosage: |
1, 10, 25 nmol/µL |
Administration: |
Microinjection (in the infralimbic cortex (IL)), once every week, 2 weeks |
Result: |
Dose-dependently prolonged transfer-latency (T-L) and produced a dose-dependent anxiolytic behavioural profile, and after 24 h, the mouse were observed small but detectable carry-over effects. In week 2, U-69593 dose-dependently prolonged T/L and produced an anxiolytic behavioural profile in the first EPM (elevated plus-maze) trial, but observed a robust anxiolytic behavioural profile. |
Animal Model: |
280-350 g, male Wistar rats[4] |
Dosage: |
0.32 mg/kg |
Administration: |
S.c. (followed 15 min later by an injection of amphetamine (2.5 mg/kg i.p.)) |
Result: |
Significantly reduced the amphetamine-stimulated increase in dialysate dopamine levels and blocked the ability of amphetamine to evoke an increase in dialysate glutamate levels. |
|
---|
性状 | Solid |
---|
溶解性数据 | |
---|
运输条件 |
Room temperature in continental US; may vary elsewhere.
|
---|
储存方式 |
Powder |
-20°C |
3 years |
In solvent |
-80°C |
6 months |
|
-20°C |
1 month |
|
---|
参考文献 | |
---|